Navigation Links
Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
Date:12/8/2008

e first infusion and 2,000 mg of ofatumumab at each subsequent infusion. Disease status is assessed every four weeks until week 28 and then every three months until disease progression or month 24.

The interim analysis included 138 treated patients (DR, n=59; BFR, n=79). Patient recruitment is ongoing and a final analysis will be conducted on the full study population, expected to be 100 patients in each group.

The primary endpoint of the study is objective response over a 24 week period from start of treatment as assessed according to the National Cancer Institute Working Group guidelines by an Independent endpoint Review Committee (IRC). Secondary endpoints included duration of response, progression free survival, time to next CLL therapy, overall survival and adverse events.

About ofatumumab

Ofatumumab is being developed to treat chronic lymphocytic leukemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing-remitting multiple sclerosis under a co-development and commercialization agreement between Genmab and GlaxoSmithKline. It is not yet approved for any indication in any country.

About CLL

CLL is the most common leukemia and one of the most common malignant lymphoid diseases.(2) Globally, leukemia accounts for some 300,000 new cases each year (2.8 percent of all new cancer cases) and 222,000 deaths.(7)

Conference Call

Genmab will hold a conference call to discuss these results tomorrow, December 9, 2008 at:

3:00 pm CEST

2:00 pm BST

9:00 am EST

The conference call will be held in English.

The dial in numbers are as follows:

+1 877 723 9518 (in the US) and ask for the Genmab conference call

+1 719 325 4812 (outside the US) and ask for the Genmab conference call <
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
4. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
5. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
9. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
10. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
11. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 According to the ... (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General ... Global Forecasts to 2019", published by MarketsandMarkets, studies the ... of 2014 to 2019. The market is expected ... of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... Ill. , Sept. 23, 2014  Medela announced ... Atlanta Biomedical Company (ABC), assigning Medela as the exclusive ... now known as the Medela Enteral Feeding Pump. Through ... to help NICU parents and healthcare professionals by offering ... The Medela Enteral Feeding Pump is integral to the ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
Breaking Medicine Technology:Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 4Medela Enters Exclusive Enteral Feeding Pump Agreement with Atlanta Biomedical Company 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4
... 10, 2011 In the year since a devastating earthquake ... and around the world have launched and supported projects to ... the New Year began, Rotary clubs started a $200,000 initiative ... outbreak of the waterborne disease. Rotary clubs worldwide ...
... Jan. 10, 2011 CoreLab Partners, Inc , ... Inc and Medifacts International, has launched a new advanced ... are pleased to announce the release of our proprietary ... development continuum by offering sponsors advanced technologies and integrated ...
Cached Medicine Technology:Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 2Rotary Clubs Remain Committed to Rebuilding Quake-Ravaged Haiti 3CoreLab Partners Launches Advanced Imaging Application 2CoreLab Partners Launches Advanced Imaging Application 3
(Date:9/23/2014)... Ore. A recent Oregon survey about an exercise ... the daily routine of elementary school students found it ... and teachers, and offered clear advantages for overly sedentary ... developed and produced by the Healthy Youth Program of ... is available nationally. , Brain Breaks leads children in ...
(Date:9/23/2014)... national report showing the benefits of preventing a ... Medicaid services was released today by the American ... Congress Must Save the Medicaid Primary Care Pay ... Access to Life-Saving Primary Care Will Expire," explains ... access to internists and pediatricians (and their related ...
(Date:9/23/2014)... Vancouver Electrician Contractors, Pro Ace, has recently announced ... in Vancouver, BC. The company will provide services on ... maintenance project or a large-scale new installation project, Pro ... needs of the individual commercial client. Pro Ace has ... affordable price. As a result, businesses of all sizes ...
(Date:9/23/2014)... September 23, 2014 The ... rhinitis (AR) is highly fragmented, with the ... formulations available, under different regulatory restrictions, with ... Europe has the most developed market, with ... allergen immunotherapy tablets (AITs) all being available. ...
(Date:9/23/2014)... SOURCE: Solutions from Our Country’s Entrepreneurs ... Rimidi Diabetes and TruClinic (TM) ... to challenges faced by patients and healthcare systems. ... The Hitachi Foundation, Village Capital, and ... investment capital, mentoring, and support needed to grow their ...
Breaking Medicine News(10 mins):Health News:'Brain Breaks' increase activity, educational performance in elementary schools 2Health News:'Brain Breaks' increase activity, educational performance in elementary schools 3Health News:Unless Congress acts, patients may soon lose access to primary care 2Health News:Unless Congress acts, patients may soon lose access to primary care 3Health News:Pro Ace Now Offers Commercial Electrical Services in Vancouver 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:Allergen extract Allergic Rhinitis Specific Immunotherapy Market to Grow $688.3m by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... ... Island man,s sense of smell and taste , ... Mineola, N.Y.(Lexis Nexis) July 8, 2009 -- Marc Grossman , senior ... N.Y., today announced that his firm has filed a civil lawsuit against the manufacturer of ...
... -- Perot Systems Corporation (NYSE: PER ) ... a Chinese-language website as part of the company,s expanded presence ... , , "Perot Systems is in the early stages ... for the reception we have received from local leaders across ...
... Chairman of the U.S. Catholic Bishops, Committee on Pro-Life ... stem cell research issued yesterday by the National Institutes ... , , "In April I criticized the NIH,s ... that under these guidelines ,federal tax dollars will be ...
... -- Chemical dependency and recovery in patients and physicians ... editorials in the July 2009 issue of Mayo ... the immense challenges, including potential tragedies, of prescription chemical ... crucial overview, direction and optimism. Addiction to ...
... July 7 DRINKiQ.com , Diageo,s ... Communicator Award as the Most Outstanding Health and Wellness web ... The site was also named runner-up in the Education Category. ... honors creative excellence for communications professionals. The program is sanctioned ...
... 7 AMB Property Corporation(R) (NYSE: AMB ), ... today announced that it has fully leased a 328,000 square ... in Hamburg to BSN medical GmbH, a leading global medical ... BSN medical,s previous commitment to 210,000 square feet (19,500 square ...
Cached Medicine News:Health News:New York Law Firm Files Lawsuit Against Manufacturer of Zicam Nasal Spray and Drugstore Chain That Sold Product 2Health News:Perot Systems Launches Website in Chinese to Support Expansion Into China 2Health News:Cardinal Rigali Criticizes Final NIH Guidelines for Destructive Stem Cell Research 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 2Health News:A comprehensive review of addiction to prescription painkillers among patients and physicians 3Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 2Health News:Diageo's DRINKiQ.com Honored as Most Outstanding Health & Wellness Site by International Academy of the Visual Arts 3Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 2Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 3Health News:AMB Property Corporation(R) Leases 440,000 SF in Hamburg 4
... Verisyse Phakic IOL is used to ... medical term for nearsightedness. With over ... procedures performed worldwide, results prove that ... effective for very nearsighted people who ...
... CELL-DYN 3200 sets a benchmark of ... scatter for WBC, RBC, PLT and ... the needs of today's laboratory. The ... differential analysis, automated sample handling, comprehensive ...
The Mini Vidas is a compact version of the Vidas system with a built-in computer, keyboard and printer. Two independent sections each accept six tests and can process up to 12 samples simultaneously....
Inquire...
Medicine Products: